Cutting Edge Research on Drug Treatment Strategies and Emerging Therapies for Alzheimer’s Disease
DOI:
https://doi.org/10.54097/meadgd26Keywords:
Alzheimer's disease, drug treatment strategies, emerging therapies, calcineurin, challenges and future.Abstract
Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by progressive cognitive decline and the memory loss. As the global population ages, the burden of AD continues to rise, highlighting the urgent need for effective treatment strategies. This abstract presents a comprehensive review of cutting edge research on drug treatment strategies and emerging therapies for AD. Recent advancements in understanding the underlying pathophysiology of AD have led to the identification of novel targets for drug development. Innovative therapeutic approaches, including disease-modifying drugs, have shown promise in preclinical and clinical studies. This thesis discusses the latest research on anti-amyloidβ (Aβ) therapies, tau-based interventions, and inflammation-targeting drugs. Additionally, emerging therapies such as immunotherapies and gene therapies, and stem cell-based treatments are explored. The thesis emphasizes the potential of calcineurin and personalized approaches in AD treatment. The integration of biomarkers and neuroimaging techniques enables early detection and intervention, facilitating more targeted and effective therapies. Furthermore, the role of lifestyle modifications, such as diet, exercise, and cognitive training, is examined in the context of AD management. This article introduces the situation of the AD and the developing trend of the research on treatment of AD. By the power of innovative drug therapies, emerging technologies and holistic approaches, there is a flush of hope of slowing disease progression, improving cognitive function, and enhancing the quality of life for individuals affected by AD.
Downloads
References
Alzheimer disease. Nat Rev Dis Primers. 2021 May 13; 7(1): 34.
Ma C, Hong F, Yang S. Amyloidosis in Alzheimer's Disease: Pathogeny, Etiology, and Related Therapeutic Directions. Molecules. 2022 Feb 11; 27(4): 1210.
Wang Jianzhi, Tian Qing. Mechanism of Tau hyperphosphorylation and its role in neuronal degeneration in Alzheimer's disease [J]. Advances in Biochemistry and Biophysics, 2012, 39 (8): 771-777.
Alzheimer disease. Nat Rev Dis Primers 7, 34 (2021).
Segerstrom SC. Personality and Incident Alzheimer's Disease: Theory, Evidence, and Future Directions. J Gerontol B Psychol Sci Soc Sci. 2020 Feb 14; 75(3): 513-521.
Chen Y, Chang L, Blennow K, Zetterberg H, Ball A J. Alzheimer's Dement. 2020. 16(S4): e041238.
Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, Gräber S, Kuder-Buletta E, LaFougere C, Laske C, Vöglein J, Levin J, Masters CL, Martins R, Schofield PR, Rossor MN, Graff-Radford NR, Salloway S, Ghetti B, Ringman JM, Noble JM, Chhatwal J, Goate AM, Benzinger TLS, Morris JC, Bateman RJ, Wang G, Fagan AM, McDade EM, Gordon BA, Jucker M; Dominantly Inherited Alzheimer Network. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nat Med. 2019 Feb; 25(2): 277-283.
Seo Y, Park KS, HaT, Kim MK, Hwang Y J, Lee J, Ryu H, Choo H, Chong Y. ACS Chem. Neurosci., 2016, 7: 1474 - 1481.
Zhang P. FuC X, Liu H H, Guo X J, Zhang Q. Gao J. Chen W J. Yuan W, Ding C F. Anal. Chem., 2021, 93: 11337 - 11345.
Duan Y M, Chen J, Jin Y, Tu QY, Wang SH, Xiang J. Anal. Chem., 2021, 93(7): 3611 -3617.
Dong H, LiJL, Huang L, Chen X, LiD H, Wang T, HuG Y, Xu J, Zhang C N, Zen K, Xiao S F, Yan Q,Wang C, Zhang C Y. Dis. Markers, 2015, 2015(9): 625659.
Chandrasekaran A R. Halvorsen K. ACS Sens., 2021, 6(9): 3176 - 3181.
Zhang X, LiuS, Song X D, Wang HW, Wang J F, Wang Y, Huang JD, Yu J H. ACS Sens., 2019, 4(9): 2140-2149.
Atri A. Current and Future Treatments in Alzheimer's Disease. Semin Neurol. 2019 Apr; 39(2): 227-240.
Marucci G, Buccioni M, Ben DD, Lambertucci C, Volpini R, Amenta F. Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease. Neuropharmacology. 2021 Jun 1; 190: 108352.
Koola MM. Galantamine-Memantine combination in the treatment of Alzheimer's disease and beyond. Psychiatry Res. 2020 Nov; 293: 113409.
Yang SJ, Zhao W, Wei Q. Activities and properties of calcineurin catalytic domain [J]. Chin Sci Bull, 2000, 45(4): 381-386.
Calvo-Rodriguez M, Bacskai BJ. Mitochondria and Calcium in Alzheimer's Disease: From Cell Signaling to Neuronal Cell Death. Trends Neurosci. 2021 Feb; 44(2): 136-151.
BioRun, Protein post-translational modification - phosphorylation, 2022.01.12, 2023.7.20.
ianqian. Effects of calcineurin on learning and memory in rats with Alzheimer's disease induced by Aβ1-42 and its related mechanisms. Guangxi Medical University, 2015.
Jing Qun. A new target of calcineurin for drug therapy of Alzheimer's disease. Chin J Pharmacol Toxicol 18(1): 71-74.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.







